1st-Half Profits Rise At Gist-Brocades

8 September 1996

Dutch company Gist-Brocades has announced net profits for the first six months of 1996 of 69.7 million guilders ($41.8 million), an increase of 8.2% on the like, year-earlier period. Earnings per share were 1.78 guilders, up 4.1%. Turnover in the first half of the year was 980.8 million guilders, a rise of 10%.

The firm said that turnover of industrial pharmaceutical products was ahead of the year-earlier period. This was attributed to acquisitions and organic growth. Due, among other things, to increases in raw material prices and other production costs, profit remained at much the same level.

G-B expects net profits for the whole of 1996 to be distinctly higher than those for the whole of 1995, assuming that there will be no excessive fluctuations in the exchange rates of major currencies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight